Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2020-04-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
2020年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年第一季度报告" which translates to "2020 First Quarter Report." It contains detailed financial statements including balance sheets, profit and loss statements, cash flow statements, and notes for the first quarter of 2020. The report is unaudited as stated in the text. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, specifically a quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2020
2020-04-28 Chinese
首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is titled "上市公告书" which translates to "Listing Announcement" or "IPO Listing Announcement". It details the company's stock listing on the Shanghai Stock Exchange's STAR Market (科创板), including stock code, issuance details, shareholder structure, lock-up periods, risk factors related to the IPO, regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, and other IPO-related information. The document is lengthy (15,000 characters) and contains comprehensive information about the IPO process, shareholders, management, and stock issuance. It is not a financial report like an annual or quarterly report, nor is it a simple announcement of a report. It is a formal listing announcement document related to the company's initial public offering and stock listing. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about the IPO and listing, not a financial report or other specific filing type.
2020-04-14 Chinese
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association (章程) for 成都先导药物开发股份有限公司 (HitGen Inc.). It includes comprehensive sections on company organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and governance rules. It references Chinese company law, securities law, and stock exchange listing rules. The content is about the internal governance framework and rules of the company rather than financial results, audit opinions, or announcements. It is not a report of financial performance or an announcement of voting results. It is a governance document detailing the company's internal rules and board/shareholder meeting procedures. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail confirm it is the actual governance document, not just an announcement or summary.
2020-04-14 Chinese
首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus (招股说明书) for an initial public offering (IPO) and listing on the Shanghai Stock Exchange STAR Market (科创板). It includes extensive risk disclosures, business descriptions, financial data, and other information typical of an IPO prospectus. The document is not an annual report, earnings release, or any other type of periodic financial report. It is also not a simple announcement or certification but a comprehensive offering document. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes such as IPO prospectuses.
2020-04-07 Chinese
首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for the company's initial public offering (IPO) and listing on the STAR Market (科创板). It details the results of the stock issuance, including the number of shares issued, pricing, allocation to strategic investors, online and offline subscription results, and the underwriting details. It includes detailed subscription statistics, allotment results, and information about the underwriting institution. The document is an announcement of the results of a capital raising event (IPO) rather than a full financial report or regulatory filing. It is not an annual or interim report, nor a management or earnings report. It is not a proxy, voting, or governance document. It is not a legal or merger announcement. The content fits best under the category of Capital/Financing Update (CAP) because it provides detailed information about the company's capital raising through the IPO and the allocation of shares. The document length is substantial and contains detailed data, confirming it is the announcement itself, not just a brief notice or report publication announcement.
2020-04-07 Chinese
首次公开发行股票并在科创板上市网下初步配售结果及网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Chengdu Lead Pharmaceutical Co., Ltd., including the offline preliminary allotment results and online lottery results for the stock issuance on the STAR Market (科创板). It includes information about the underwriting, strategic placement, subscription details, allotment numbers, subscription procedures, and related investor information. The document is not a financial report, earnings release, or management discussion but rather an official announcement of the results of a capital raising event (IPO). It contains detailed allocation and subscription results, which are typical for a Capital/Financing Update. There is no indication that this is a proxy statement, voting results, or a regulatory filing of a different nature. The document length is substantial and contains substantive data about the capital issuance and allotment. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-02 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.